_edited_edited_edited.png)
At DrugReKindle, we transform setbacks into breakthroughs. Our mission is to repurpose drugs that have failed in clinical trials, leveraging our cutting-edge AI platform to discover new therapeutic indications. For investors, this means recovering financial losses and maximizing returns by turning previously unviable drugs into marketable solutions. For patients, it means renewed hope and access to new treatments that can significantly improve their lives.
How it works
1
Advanced Target Screening
Uniquely in-silico screening on over 20,000 targets enabling exploration of therapeutic possibilities.
2
Predictive Modeling and Orthogonal Analysis
Combines advanced Pocketome similarity analysis, ligand-based modeling with AI, and precise molecular docking simulations, not combined elsewhere.
3
Efficient Validation
All computational predictions are rigorously biologically validated, ensuring actionable insights.
STRATEGIC APPROACH
TO OBTAIN SOLID NEW IP
Computational power and AI are meaningless without the expertise to harness them—our team, with experience from Pfizer, Novartis, Roche, and GSK, orchestrates a complex, multidisciplinary, and multilayered system.
Discover how DrugReKindle can turn stalled drug development into successful therapies—if you're an investor or part of the pharmaceutical industry, contact us to explore this exciting and impactful market opportunity.
​
Stay tuned for further information !